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Evidence that 1,25-Dihydroxyvitamin D3
Inhibits the Hepatic Production
of 25-Hydroxyvitamin D in Man
Norman H. Bell, Sheryl Shaw, and Russell T. Tumer
Veterans Administration Medical Center and Departments of

Medicine and Pharmacology, Medical University ofSouth
Carolina, Charleston, South Carolina 29403

Abstract. Previous in vitro studies in rachitic
rat liver suggested that 1,25-dihydroxyvitamin D inhibits the hepatic production of 25-hydroxyvitamin D
(25-OHD). An investigation therefore was carried out
in eight normal subjects to determine whether concomitant administration of 1,25-dihydroxyvitamin D3
[1,25(OH)2D3 J would alter the response of serum 25OHD to challenge with vitamin D. In control studies,
vitamin D, 100,000 U/d for 4 d, significantly increased
mean serum 25-OHD, from 26.3±2.9 to 66.7±12.6 ng/
ml (P < 0.01). In contrast, 1,25(OH)2D3, 2 Ag/d for 4
d, completely prevented an increase in serum 25-OHD
in response to the same dose of vitamin D in the same
individuals (25.1±2.2 vs. 27.4±5.3 ng/ml, NS). In a
post-control study in seven of the normal subjects,
vitamin D again significantly increased mean serum 25OHD, from 18.2±3.1 to 42.8±4.7 ng/ml (P < 0.001).
In each of the three studies, mean serum calcium,
phosphorus, and creatinine did not change and remained
within the normal range. Whereas mean urinary calcium
did not change in response to vitamin D alone during
the 4 d of the two control studies, it increased significantly
in the study in which vitamin D and 1,25(OH)2D3 were
given together. A dose-response inhibition of the response
of serum 25-OHD to vitamin D by 1,25(OH)2D3 was
demonstrated in two of the normal subjects. The results
provide evidence that 1,25(OH)2D3 inhibits the hepatic
synthesis of its precursor 25-OHD in man.
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Introduction
Available evidence indicates that 1,25-dihydroxyvitamin D3
[1 ,25(OH)2D3]' inhibits the production of 25-hydroxyvitamin
D (25-OHD) by the liver. Thus, 1,25(OH)2D3 inhibited the in
vitro synthesis of 25-OHD by liver homogenates and perfused
liver from rachitic rats at a concentration of 100 pg/ml (1). A
dose-response inhibition of synthesis of 25-OHD at this and
higher concentrations of 1,25(OH)2D3 was also demonstrated.
Accordingly, the present studies were carried out to determine
whether concomitant administration of 1,25(OH)2D3 alters the
increase in serum 25-OHD that occurs after vitamin D challenge
in normal adult human subjects.

Methods
Eight normal adult subjects, four men and four women, were studied
by methods previously described (2). They ranged in age from 24 to
35 yr. All of them were hospitalized at the General Clinical Research
Center of the Medical University of South Carolina. Each gave
informed consent. They were given a constant daily diet estimated to
contain 400 mg/d of calcium and 900 mg/d of phosphorus, and a
constant fluid intake. Three studies were conducted in sequence. In
the first study, all subjects were given vitamin D2, 2.5 mg (100,000 U)
per day for 4 d, as a single morning dose. In the second study, all of
them were given 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] in divided
doses at intervals of 12 h for the 4-d period together with the same
dose of vitamin D. In the third study, vitamin D was given again by
itself for 4 d to seven of the subjects. Fasting blood samples were
obtained on the first day, before vitamin D either with or without
1,25(OH)2D3, and again on the fifth day, 24 h after the last dose of
the vitamin and, when 1,25(0H-)D3 was given, 12 h after the last dose
for determination of serum calcium (3), phosphorus (4), and creatinine
(5) by automated methods and for measurement of serum 25-OHD.
Serum 1,25(0H)2D also was measured in the study in which
1,25(OH)2D3 was administered. 24-h urines were collected and analyzed
for calcium (3).
1. Abbreviations used in this paper: 1,25(OH)2D, 1,25-dihydroxyvitamin
D; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; 25-OHD, 25-hydroxyvitamin D.

Serum 25-OHD was measured in duplicate at two concentrations
by the competitive protein binding method with vitamin D-deficient
rat serum (6) after extraction with methanol/methylene chloride 2:1
(vol/vol), alkaline backwash, chromatography of samples on Lipidex5000 (Packard Instrument Co., Downers Grove, IL), and elution with
hexane/chloroform 85:15 (vol/vol) as previously reported (7, 8). The
mean±SD in normal subjects is 23.3±11.4 ng/ml (n = 42). Serum
1,25(OH)2D was measured in duplicate by the chick intestinal receptor
method (7) after extraction without high performance liquid chromatography by the procedure of Reinhardt et al. (9). The mean±SD in
normal subjects is 25.9±12.1 pg/ml (n = 27). The t test was used to
determine the statistical significance of differences between paired and
unpaired samples. Statistical analyses were conducted with a calculator
(model 9815A; Hewlett-Packard Co., Palo Alto, CA).

simultaneously administered 1,25(OH)2D3 completely prevented an increase in serum 25-OHD produced by vitamin D
and increased urinary calcium significantly. Individual values
for serum 25-OHD in the normal subjects during the first two
studies are depicted in Fig. 1. Dose-response inhibition by
1,25(OH)2D3 of the increases in serum 25-OHD in response
to vitamin D in two of the normal subjects was also observed

(Fig. 2).
In the second study, there was only a modest increase in
mean serum 1,25(OH)2D in response to 1,25(OH)2D3, but the
increment was not statistically significant. This small change
is attributed to the rapid metabolism of the metabolite after
its oral administration (10). Nevertheless, two biologic effects
of 1,25(OH)2D3 were demonstrated, inhibition of hepatic production of 25-OHD and increase in urinary calcium.

Results
The results are summarized in Tables I and II. In the first
study, mean serum 25-OHD increased significantly in response
to vitamin D, 100,000 U/d for 4 d, and mean serum calcium,
phosphorus, and creatinine did not change in the eight normal
subjects (Table I). In contrast, in the second study, mean
serum 25-OHD, calcium, phosphorus, and creatinine did not
change in the same eight individuals in response to the same
dose of vitamin D when 1,25(OH)2D3, 2 ,ug/d, was given
concomitantly in divided doses for the 4 d. In the third study
in seven of the subjects, mean serum 25-OHD again increased
significantly in response to vitamin D by itself, and mean
serum calcium, phosphorus, and creatinine did not change.
Mean urinary calcium increased in response to 1,25(OH)2D3
and vitamin D during the 4 d of that study but was not altered
by vitamin D alone in the other two studies (Table II). Thus,

Discussion
Previous findings in normal adult subjects indicate that 25hydroxyvitamin D- 1 a-hydroxylase in the kidney is much more
tightly regulated than vitamin D-25-hydroxylase in the liver
(11, 12). When vitamin D in pharmacologic doses (100,000
U/d for 4 d) is administered to normal subjects, mean serum
25-OHD increases significantly, but mean serum 1,25(OH)2D
does not change (11, 12). Indeed, vitamin D intoxication is
characterized by and results from abnormal elevation of serum
25-OHD, and serum 1,25(OH)2D is either normal or only
minimally elevated (13). Parathyroid hormone is the major
regulator of the renal production of 1,25(OH)2D. Values are
low in hypoparathyroidism, may be increased in primary

Table I. Effects of Vitamin D and 1,25(OH)2D3 on Serum Calcium,
Phosphorus, Creatinine, 25-OHD, and J,25(OH)2D in Normal Subjects
Serum
Treatment

Study 1 (8)
Control
Vitamin D
P value

Calcium

Phosphorus

Creatinine

25-OHD

1,25(OH)2D

mg/dl

mg/dl

mg/dl

ng/ml

pg/mt

9.1±0.1
9.2±0.2
NS

4.0±0.2
4.1±0.1
NS

0.9±0.1
0.9±0.1
NS

26.3±2.9
66.7±12.6
<0.01

9.2±0.2
9.2±0.2
NS

4.0±0.2
4.4±0.2
NS

1.0±0.1
1.0±0.1
NS

25.1±2.2
27.4±5.3
NS

8.8±0.2
9.0±0.1
NS

4.1±0.3
4.0±0.2
NS

1.0±0.1
1.0±0.1
NS

18.2±3.1
42.8±4.7

Study 11 (8)
Control
Vitamin D + 1,25(OH)2D3
P value

Study III (7)
Control
Vitamin D
P value

<0.001

Results are presented as mean±SE. Figures in parentheses are the number of subjects.
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23.6±1.3
32.2±3.4
NS

Table II. Effects of Vitamin D and 1,25(OH)2D3
on Urinary Calcium in Normal Subjects

Normal mole

u
c

1

3

2

4

189±20

205±20

190±18

252±27*

296±40*

310±47*

208±25

206±25

204±20

203±17

* P < 0.01 vs. day I of vitamin D and 1,25(OH)2D3.
P
F < 0.02 vs. day I of vitamin D and 1,25(OH)2D3.

hyperparathyroidism, and are increased by the administration
of parathyroid extract in patients with hypoparathyroidism
(14-16). Hypercalcemia caused by vitamin D intoxication is
associated with suppression of circulating immunoreactive
parathyroid hormone and urinary cyclic 3'5'-adenosine monophosphate (17). Also, adaptation from a high to a low calcium
diet is mediated by increases in circulating parathyroid hormone
and 1,25(OH)2D (18).
Our results show that 25 hydroxylation of vitamin D is
impaired by exogenously administered 1,25(OH)2D3. Thus,
there appears to be feedback regulation of hepatic synthesis of
25-OHD by 1,25(OH)2D3 in human subjects in vivo as there
is in rat liver in vitro (1). A number of clinical observations
support this concept. First, we described two patients with
sarcoidosis, hypercalcemia, and increased circulating
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Figure 1. The effects of vitamin D, 100,000 U/d for 4 d,
by itself and together with
1,25(OH)2D3, 2 ug/d for 4 d,
on serum 25-OHD in eight
normal adult subjects. The vitamin D was given as a single
morning dose, and the
1,25(OH)2D3 was given in divided doses, 1 Isg every 12 h
for 4 d.

N. H. Bell, S. Shaw, and R. T. Turner

Ir

U
1,5

,

5

Days

Figure 2. The effects of vitamin D, 100,000 U/d for 4 d, by itself and
together with 1,25(OH)2D3, on serum 25-OHD in two normal subjects. The vitamin D was given as a single morning dose, and the
1,25(OH)2D3 was given in divided doses every 12 h for 4 d. Note
that one of the subjects required 4 sg/d of 1,25(OH)2D3 for maximum suppression (a) and that the other suppressed with smaller
doses of 1,25(OH)2D3 (b).

1,25(OH)2D who had values for serum 25(OH)D that were
low or low-normal and ranged from 5 to 9 ng/ml (9). Second,
one patient with vitamin D-dependent rickets type II and
elevated serum 1,25(OH)2D was reported to have "apparent
defective synthesis" of 25-OHD (19). In this individual, serum
25-OHD was in the lower range of normal, 18.6 ng/ml, despite
earlier administration of large doses of vitamin D. Third,
serum 25-OHD was reported to fall progressively and significantly in a group of 25 postmenopausal women who were
being treated chronically with 1,25(OH)2D3 (20). Fourth, mean
serum 25-OHD was significantly decreased and mean serum
1,25(OH)2D was significantly increased in a group of patients
with hyperphosphatemic tumoral calcinosis as compared with
values in normal subjects and nonaffected family members
(21). Finally, we conducted studies in a patient who had had
hypercalcemia and elevated serum 1,25(OH)2D and did not
have sarcoidosis while he was normocalcemic after treatment
with prednisone (Bell, N. H., unpublished observations).
Whereas his serum 1,25(OH)2D, serum calcium, and urinary
calcium increased abnormally in response to vitamin D, his
serum 25-OHD, which initially was abnormally low, never
rose above 10 ng/ml. The findings indicate that circulating 25OHD may be reduced in patients with abnormal elevation of
serum 1,25(OH)2D or by administration of 1,25(OH)2D3.
There is also evidence that feedback inhibition of hepatic
production of 25-OHD may be of physiologic importance in
children. We reported previously that whereas in adults 25OHD production is loosely regulated and 1,25(OH)2D production is tightly regulated in response to vitamin D challenge,
the opposite is true in children (12). Vitamin D, 1,500 U/kg
body wt per d for 4 d, produced modest but significant

increases in mean serum calcium, from 9.5 to 9.8 mg/dl; in
mean serum 25-OHD, from 25 to 34 ng/ml (an average of
36%); and in mean serum 1,25(OH)2D, from 34 to 42 pg/ml
(an average of 24%) in a group of 12 normal children. Serum
calcium, serum 25-OHD, and serum 1,25(OH)2D remained
within the normal range in all subjects. The lack of a more
substantial increase in serum 25-OHD probably resulted from
the increases in serum 1,25(OH)2D and consequent inhibition
of 25 hydroxylation of the vitamin. Thus, it appears that
feedback regulation of synthesis of the precursor 25-OHD by
1,25(OH)2D protects against abnormal increases in serum
1,25(OH)2D of normal children in whom 1,25(OH)2D production is loosely regulated.
These findings contrast with those we observed in six
children with the Williams syndrome. In those individuals,
vitamin D, 1,500 U/kg body wt per d for 4 d, produced a
marked increase in mean serum 25-OHD, from 16.7 to 66.8
ng/ml (an average of 298%) (2). Mean serum calcium and
1,25(OH)2D did not change. The lack of tight regulation of
serum 25-OHD in these children probably resulted from lack
of an increase in serum 1,25(OH)2D, which would diminish
hydroxylation of vitamin D. The exaggerated response of
serum 25-OHD in the children with the syndrome therefore
appears to be secondarily related to tight regulation ofcirculating
1,25(OH)2D in response to vitamin D and not to any intrinsic
abnormality in 25-hydroxylation of the vitamin.
In summary, the present and previous observations provide
strong evidence that 25 hydroxylation of vitamin D is regulated
by circulating 1,25(OH)2D. Thus, 1,25(OH)2D acts to limit
production of its precursor. In adults this feedback regulation
of synthesis of the precursor, together with tight regulation of
renal production of the most active metabolite of vitamin D,
provides mechanisms that protect against an abnormal elevation
of circulating 1,25(OH)2D. The inadequacy of feedback regulation of 25-OHD production by itself to prevent abnormal
increases in circulating 1,25(OH)2D in diseases in which
1,25(OH)2D production is unregulated, however, is attested to
by the hypercalcemia and abnormal calcium metabolism that
may spontaneously occur in sarcoid, (9, 22, 23), disseminated
candidiasis (24), and lymphoma (25). The mechanism by
which the feedback regulation of 25-OHD production occurs
has not been established. In view of the almost 1,000-fold
difference in concentration of the two metabolites in the
circulation, it is not likely that 1,25(OH)2D3 acts to competitively inhibit 25 hydroxylation of the vitamin. Further studies
are needed to determine how regulation is mediated.
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